UK competition authority accuses Concordia of price gouging

21 November 2017
concordiabig

The Competition and Markets Authority (CMA), the UK’s primary competition and consumer authority, has provisionally found that Concordia (TSX: CXR) abused a dominant position to overcharge the country’s National Health Service (NHS) for an essential thyroid drug.

The CMA says that the Canadian pharma and medical devices company charged the NHS more than £34 million ($45 million) last year for liothyronine tablets, an increase from around £600,000 in 2006.

Concordia was the only supplier of the drug, which is used to treat hypothyroidism, a condition caused by a deficiency of the thyroid hormone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical